AstraZeneca and SK Chemicals Collaborate to Manufacture Sidapvia- Diabetes Combination Drug
AstraZeneca collaborates with SK Chemicals to manufacture Sidapvia, a novel diabetes combination drug, for the next decade at SK's facility in Korea.
According to a regulatory filing, SK Chemicals of Korea has entered into an agreement with AstraZeneca to manufacture the diabetes drug Sidapvia for the rest of the decade.
The manufacturing will take place at SK's facility in Cheongju, the capital city of North Chungcheong Province.
Furthermore, SK Chemicals will be responsible for the distribution of Sidapvia within Korea. Specific details regarding other terms of the agreement have not been disclosed at this time.
The deal makes the companies’ partnership stronger. In 2020, they joined forces to create Sidapvia. At first, AZ provided the necessary ingredients and money for research. Then, SK took over to develop the product and test it on people in Korea.
Sidapvia, a unique drug blend of Farxiga from AZ and Januvia from Merck, was approved in Korea last month, marking the first of its kind globally.
This partnership shows how working together can lead to exciting new medicines, benefiting people everywhere who might need Sidapvia’s unique treatment.